Chengdu SG-Biotech

Chengdu SG-Biotech is a China-based animal health biotech focused on veterinary vaccines, especially swine vaccines, along with related diagnostic and technical services. The company was founded in 2003, formerly operated as Chengdu Tianbang Biological Products, and was acquired by Xianfeng Holdings in 2021 before being renamed in October 2021. Its business centers on R&D, manufacturing, and commercialization of live and inactivated veterinary vaccines, supported by in-house process technologies and laboratory service capabilities. The company reports three vaccine production workshops, eight independent production lines, and annual capacity of about 15 billion doses for livestock and poultry. Publicly visible product focus areas include pseudorabies, classical swine fever, and mixed immunization strategies for major swine diseases. It also operates veterinary diagnostic and quality-assessment platforms, making it a commercial-stage animal vaccine and animal diagnostics platform company rather than a human therapeutics developer.